Trade name: ID-Card Diaclon Abo / D + Proof Reversal. Technical Name: Immunohematology - ABO - Monoclonal Origin. ANVISA registration number: 80004040061. Risk class: IV. Affected model: 00 000 000 0012 35. Lot numbers / series affected: Lot: 50092.95.19 - ID-Card numbering sequence from 23,000 to 31,000 의 안전성 경고

Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.

1. We request that the customer verify that the ID-Card numbering sequence present on the DiaClon ABO / D + Reverse Proof Lot 50092.95.19 product's internal label is between 23,000 and 31,000 2. The numbering sequence of the ID-Card is 23,000 to 31,000, immediately stop using the DiaClon ABO / D + Reverse Proof lot 50092.95.19 card, identify and segregate the box (s) for subsequent return to Bio-Rad 3. Inform the quantity of boxes in your stock that have ID-Cards with the numbering sequence between 23,000 and 31,000, so that we can carry out product replacement. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link Additional information: - Date of identification of the problem by the company: 11/04/2018 - Date of notification notice to Anvisa: 04/18/2018 The company that owns the affected product is responsible for contacting its customers in a timely manner. to ensure the effectiveness of the Field Action in progress. It stands out the joint responsibility of the distribution chain and use of health products in maintaining its quality, safety and efficacy, as well as the effectiveness of the Field Action, expressed by RDC 23/2012: "(...) Art 2 ° A holder of registration of health product is the holder of the registration / registration of health product with Anvisa. Single paragraph. The registration holder, as well as other agents involved from the production to the use of the product, or discarding it when applicable, are jointly and severally responsible for maintaining the quality, safety and efficacy of the health products to the final consumer. Art. 12 Distributors of health products shall forward to the registration holder, in a timely manner, the distribution map and other information requested for the notification and execution of field actions. (...) "